Preprints.org · 2019 · 21 citations · 77 references
MedicineInfectious DiseasesPharmacologyDrug DiscoveryImmunizationVirologyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyViral InfectionsViral VaccinesAntiviral Agent SelectionAntiviral Drug DesignAntiviral Safety AssessmentAntiviral SpectrumAntiviral TherapeuticsAntiviral TreatmentBroad-spectrum Antiviral AgentsCombination Antiviral Therapy
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs) could provide additional protection of general population from emerging and re-emerging viral diseases reinforcing the arsenal of available antiviral options. Here, we reviewed development process of BSAAs and summarized the information on 119 safe-in-man agents in freely accessible database (https://drugvirus.info/). The number of BSAAs will be increased, their developmental status will be updated, spectrum of their indications will be expanded, as well as BSAA combinations will be approved pending the results of further pre-clinical and clinical studies.
77
Spencer L James, Degu Abate, Kalkidan Hassen Abate et al. · The Lancet · 2018 · 14K citations · Full text
Lionel A. Mandell, Richard G. Wunderink, Antonio Anzueto et al. · Clinical Infectious Diseases · 2007 · 6.2K citations · Full text
The Lancet · 2018 · 4.2K citations · Full text
PubChem 2019 update: improved access to chemical data
Sunghwan Kim, Jie Chen, Tiejun Cheng et al. · Nucleic Acids Research · 2018 · 3.4K citations · Full text
Simon I Hay, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · The Lancet · 2017 · 2.2K citations · Full text
Public Health, Health Policy, Population Health Sciences +17